
We are pleased to inform you that we will be attending CPHI CHINA 2024 from June 19 to 21, 2024, our booth number is W7B56.

English name:Lifitegrast Chemical name:(S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid CAS: 1025967-78-5 Original research company: Shire Pharmaceutical Company, UK Trade name:Xiidra Registration classification: Raw materials for 3 categories, eye drops for 3 categories. Dosage specification: 50mg / mL(5%),0.2ml/, 5 per bag, 60 per box. Indication: Xiidra (lifitegrast eye solution) 5% is a lymphocyte function-associated antigen-1 (LFA-1) antagonist for the treatment of signs and symptoms of dry eye disease (DED

On February 5th,2024 PM, Jiangsu Runan Pharmaceutical co., LTD. All staff gathered in Huai'an ShuXin hotel held 2023 annual work commendation meeting ,the annual ceremony is divided into annual worl summary commendation

A spring work beginning, everything behavior first.The New Year began, all walks of life began busy. On February 18th, the first day of work after the Spring Festival, in order to promote the orderly resumption of work and production,

Warmly celebration for 2023CPHI Barcelona ,customers from all over the world stand by our booth and communicate product details. See you next year.

In the pharmaceutical industry, active pharmaceutical ingredients (APIs) with proven efficacy and safety profiles form the foundation of effective treatments. Bromhexine Hydrochloride (CAS 611-75-6) is a widely recognized expectorant used in the management of acute and chronic respiratory conditions. As a subsidiary of Jiangsu Zhengda Qingjiang Pharmaceutical Co., Ltd., Run'an Pharmaceutical manufactures this API in a state-of-the-art facility that complies with international GMP standards. This article provides an overview of the product's specifications, applications, and the manufacturing excellence that ensures its quality and reliability for global pharmaceutical markets.